方盛制药放弃优先受让权合伙份额比例降至5.88%

财中社12-16

财中社12月16日电方盛制药（603998）发布关于公司参与投资设立的并购基金合伙人合伙份额发生变动的提示性公告。公告中提到，广州迈普再生医学科技股份有限公司以3000万元认购珠海横琴中科建创投资合伙企业（有限合伙）新增的2649万元合伙份额，公司选择放弃优先受让权。此次合伙份额变动后，公司的合伙份额比例由7.43%下降至5.88%。具体持有情况显示，公司认缴出资额为750万元，实缴出资额也为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2491615470?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-16 19:26","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2491615470","market":"sh","top_or_hot":-1,"title":"方盛制药放弃优先受让权 合伙份额比例降至5.88%","media":"财中社","content":"<div>\n<p>财中社12月16日电方盛制药（603998）发布关于公司参与投资设立的并购基金合伙人合伙份额发生变动的提示性公告。公告中提到，广州迈普再生医学科技股份有限公司以3000万元认购珠海横琴中科建创投资合伙企业（有限合伙）新增的2649万元合伙份额，公司选择放弃优先受让权。此次合伙份额变动后，公司的合伙份额比例由7.43%下降至5.88%。具体持有情况显示，公司认缴出资额为750万元，实缴出资额也为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216200926ab7c4de3&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>方盛制药放弃优先受让权 合伙份额比例降至5.88%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n方盛制药放弃优先受让权 合伙份额比例降至5.88%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-16 19:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216200926ab7c4de3&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>财中社12月16日电方盛制药（603998）发布关于公司参与投资设立的并购基金合伙人合伙份额发生变动的提示性公告。公告中提到，广州迈普再生医学科技股份有限公司以3000万元认购珠海横琴中科建创投资合伙企业（有限合伙）新增的2649万元合伙份额，公司选择放弃优先受让权。此次合伙份额变动后，公司的合伙份额比例由7.43%下降至5.88%。具体持有情况显示，公司认缴出资额为750万元，实缴出资额也为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216200926ab7c4de3&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603998","symbol_name":"方盛制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216200926ab7c4de3&s=b","article_id":"2491615470","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216200926ab7c4de3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2491615470","pubTimestamp":1734348415,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"财中社12月16日电方盛制药 发布关于公司参与投资设立的并购基金合伙人合伙份额发生变动的提示性公告。公告中提到，广州迈普再生医学科技股份有限公司以3000万元认购珠海横琴中科建创投资合伙企业新增的2649万元合伙份额，公司选择放弃优先受让权。此次合伙份额变动后，公司的合伙份额比例由7.43%下降至5.88%。2024年前三季度，方盛制药实现收入13.48亿元，归母净利润2.28亿元。文章来源：财中社方盛制药放弃优先受让权 合伙份额比例降至5.88%","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603998":"方盛制药","BK0060":"抗癌","BK0239":"医药制造"},"translate_title":"Fangsheng Pharmaceutical gave up its preferential right and the proportion of partnership shares dropped to 5.88%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603998":1},"content_text":"财中社12月16日电方盛制药（603998）发布关于公司参与投资设立的并购基金合伙人合伙份额发生变动的提示性公告。公告中提到，广州迈普再生医学科技股份有限公司以3000万元认购珠海横琴中科建创投资合伙企业（有限合伙）新增的2649万元合伙份额，公司选择放弃优先受让权。此次合伙份额变动后，公司的合伙份额比例由7.43%下降至5.88%。具体持有情况显示，公司认缴出资额为750万元，实缴出资额也为750万元。此次变动不会对公司的合并报表范围产生影响，也不会损害公司的利益。2024年前三季度，方盛制药实现收入13.48亿元，归母净利润2.28亿元。文章来源：财中社原标题：方盛制药放弃优先受让权 合伙份额比例降至5.88%","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491615470"}

方盛制药放弃优先受让权 合伙份额比例降至5.88%

精彩评论

方盛制药放弃优先受让权合伙份额比例降至5.88%